IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

Chronic graft-versus-host disease (cGvHD) remains the most relevant factor affecting survival after allogeneic hematopoietic stem cell transplantation (alloHSCT). Besides corticosteroids (and ibrutinib in the USA), there is no established therapy for cGvHD. Tocilizumab, a humanized IgG1 IL6-receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kattner, Anna-Sophia, Holler, Ernst, Holler, Barbara, Klobuch, Sebastian, Weber, Daniela, Martinovic, Danilo, Edinger, Matthias, Herr, Wolfgang, Wolff, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069928/
https://www.ncbi.nlm.nih.gov/pubmed/32086584
http://dx.doi.org/10.1007/s00277-020-03968-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069928/
https://www.ncbi.nlm.nih.gov/pubmed/32086584
http://dx.doi.org/10.1007/s00277-020-03968-w

Ejemplares similares